ClinicalTrials.gg
RecruitingNCT07080216Updated Jan 5, 2026

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

A Phase 1/2 interventional study of ZG005 and Gecacitinib in Cervical Cancer, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Planned enrollment
141st of 360
120 · median 90
Started
2025
with 43 others
Phase 1/2
26 of 455
13 open now
Primary completion
2027-08
later than 167 of 239 live
Registered
410th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 141st largest by planned enrollment of the 360 interventional ones that give a count, is one of 44 that started in 2025, is one of 26 in phase 1/2, reaches primary completion later than 167 of the 239 other live ones, and was the 410th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fully understand the study and voluntarily sign the form.
  • Female 18-75 years of age;
  • (ECOG) Performance Status of 0 or 1.
  • or cytologically confirmed advanced cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.

Exclusion criteria

Exclusion Criteria:

  • Patients were deemed unsuitable for participating in the study by the investigator for any reasons.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    PART 1(phaseⅠ)

    Part 1 is a dose exploratory study of ZG005 combined with gecaxitinib ± bevacizumab to evaluate the tolerability and safety of the combination regimen

    Biological: ZG005 · Drug: Gecacitinib · Biological: Bevacizumab

  • Experimental
    PART 2(phase II)

    Part 2 is a dose expansion study to further evaluate the safety and preliminary efficacy of the combination regimen identified in Part 1

    Biological: ZG005 · Drug: Gecacitinib · Biological: Bevacizumab

Interventions

  • BiologicalZG005

    ZG005 20mg/kg, intravenous infusion(IV), once every 3 weeks (Q3W)

  • Part 1: Cohort A:Gecacitinib is administered continuously until the end of treatment; Cohort B:Gecacitinib is administered continuously from CnD1 to D14, and discontinued from CnD15 to D21;Part 2:Gecacitinib for dose exploratory stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose escalation stage.

  • BiologicalBevacizumab

    Bevacizumab 7.5 mg/kg,intravenous infusion(IV), once every 3 weeks (Q3W)

06

What researchers measure

Primary outcomes

  1. Adverse Event (AE)

    Time frame: Up to 2 years

  2. Objective response rate (ORR)

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.

Of 53 industry-sponsored phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 75. This study's planned 23 months is below that.

Counting every sponsor, half of 81 studies reached it within 62 months; a quarter within 36 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2025
First posted
Jul 23, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07080216
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Sep 23, 2025
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 5, 2026

Study contacts

Yongsheng Chu
Contact
chuys@zelgen.com
+86-0512-57309965
Jason Wu
study chair · Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilvanstomig

Start the discussion